Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.
about
BIRC6 mediates imatinib resistance independently of Mcl-1.Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.Minimal Residual Disease Eradication in CML: Does It Really Matter?Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.Opposing effects of low versus high concentrations of water soluble vitamins/dietary ingredients Vitamin C and niacin on colon cancer stem cells (CSCs).Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.Eradication of CML stem cells.Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.Focal Adhesion Kinase as a Potential Target in AML and MDS.The BCL-2 arbiters of apoptosis and their growing role as cancer targets.Integrated functional and mass spectrometry-based flow cytometric phenotyping to describe the immune microenvironment in acute myeloid leukemia.Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.Disruption of Wnt/β-catenin exerts anti-leukemia activity and synergizes with FLT3 inhibition in FLT3-mutant acute myeloid leukemia.Pathways and mechanisms of venetoclax resistance.
P2860
Q36375641-BCED7DDB-AA7E-4191-A655-BB68CBB1DB0EQ37399824-9DA3E1A5-0F27-4C0E-9585-E0F670B97DF6Q38602633-BBCA7ED6-6877-4C09-98FC-6E471161F066Q38636162-4B118701-F162-4C90-9D09-65E04679F691Q38649985-FF458898-F138-41E0-98AD-BC7C3F2235E3Q38892306-8BED2010-2661-496C-B218-914C9587CC59Q42330444-1508491C-02A2-4492-8CC1-734B5BB5D72AQ46370948-547EB274-80AE-42BD-84FD-468FA8E8EBD4Q46471789-F2F49021-C20D-4229-A3A3-8D89B84CF15DQ47166330-D10C3CFA-7C18-4723-A69B-AF9CFD961737Q47414064-532C2C66-58BE-4FF3-9F0A-C1954633A141Q48029219-14BE7BDD-CE1B-4FA4-A89F-1F332366B0E9Q49791849-79D59E5A-5244-4F96-AC4C-50BB198F18C9Q51160342-E9D8E8C5-4248-42F3-A022-51A2C973D3BA
P2860
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combined targeting of BCL-2 an ...... c myeloid leukemia stem cells.
@en
Combined targeting of BCL-2 an ...... c myeloid leukemia stem cells.
@nl
type
label
Combined targeting of BCL-2 an ...... c myeloid leukemia stem cells.
@en
Combined targeting of BCL-2 an ...... c myeloid leukemia stem cells.
@nl
prefLabel
Combined targeting of BCL-2 an ...... c myeloid leukemia stem cells.
@en
Combined targeting of BCL-2 an ...... c myeloid leukemia stem cells.
@nl
P2093
P2860
P50
P1476
Combined targeting of BCL-2 an ...... c myeloid leukemia stem cells.
@en
P2093
Bing Z Carter
Duncan H Mak
Hongsheng Zhou
Joel D Leverson
Po Yee Mak
Ravi Bhatia
Wendy Schober
Xuelin Huang
P2860
P304
P356
10.1126/SCITRANSLMED.AAG1180
P407
P577
2016-09-01T00:00:00Z